PT - JOURNAL ARTICLE AU - Rentsch, Christopher T AU - Beckman, Joshua A AU - Tomlinson, Laurie AU - Gellad, Walid F AU - Alcorn, Charles AU - Kidwai-Khan, Farah AU - Skanderson, Melissa AU - Brittain, Evan AU - King, Joseph T AU - Ho, Yuk-Lam AU - Eden, Svetlana AU - Kundu, Suman AU - Lann, Michael F AU - Greevy, Robert A AU - Ho, P. Michael AU - Heidenreich, Paul A AU - Jacobson, Daniel A AU - Douglas, Ian J AU - Tate, Janet P AU - Evans, Stephen JW AU - Atkins, David AU - Justice, Amy C AU - Freiberg, Matthew S TI - Early initiation of prophylactic anticoagulation for prevention of COVID-19 mortality: a nationwide cohort study of hospitalized patients in the United States AID - 10.1101/2020.12.09.20246579 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.09.20246579 4099 - http://medrxiv.org/content/early/2020/12/11/2020.12.09.20246579.short 4100 - http://medrxiv.org/content/early/2020/12/11/2020.12.09.20246579.full AB - Importance Deaths among patients with coronavirus disease 2019 (COVID-19) are partially attributed to venous thromboembolism and arterial thromboses. Anticoagulants prevent thrombosis formation, possess anti-inflammatory and anti-viral properties, and may be particularly effective for treating patients with COVID-19.Objective To evaluate whether initiation of prophylactic anticoagulation within 24 hours of admission is associated with decreased risk of death among patients hospitalized with COVID-19.Design Observational cohort study.Setting Nationwide cohort of patients receiving care in the Department of Veterans Affairs, the largest integrated healthcare system in the United States.Participants All patients hospitalized with laboratory-confirmed SARS-CoV-2 infection March 1 to July 31, 2020, without a history of therapeutic anticoagulation.Exposures Prophylactic doses of subcutaneous heparin, low-molecular-weight heparin, or direct oral anticoagulants.Main Outcomes and Measures 30-day mortality. Secondary outcomes: inpatient mortality and initiating therapeutic anticoagulation.Results Of 4,297 patients hospitalized with COVID-19, 3,627 (84.4%) received prophylactic anticoagulation within 24 hours of admission. More than 99% (n=3,600) received subcutaneous heparin or enoxaparin. We observed 622 deaths within 30 days of admission, 513 among those who received prophylactic anticoagulation. Most deaths (510/622, 82%) occurred during hospitalization. In inverse probability of treatment weighted analyses, cumulative adjusted incidence of mortality at 30 days was 14.3% (95% CI 13.1-15.5) among those receiving prophylactic anticoagulation and 18.7% (95% CI 15.1-22.9) among those who did not. Compared to patients who did not receive prophylactic anticoagulation, those who did had a 27% decreased risk for 30-day mortality (HR 0.73, 95% CI 0.66-0.81). Similar associations were found for inpatient mortality and initiating therapeutic anticoagulation. Quantitative bias analysis demonstrated that results were robust to unmeasured confounding (e-value lower 95% CI 1.77). Results persisted in a number of sensitivity analyses.Conclusions and Relevance Early initiation of prophylactic anticoagulation among patients hospitalized with COVID-19 was associated with a decreased risk of mortality. These findings provide strong real-world evidence to support guidelines recommending the use of prophylactic anticoagulation as initial therapy for COVID-19 patients upon hospital admission.Competing Interest StatementJAB reports consulting with Amgen, Bayer, JanOne, and Janssen. He serves on the Data Safety Monitoring Committee for Novartis. PMH is supported by grants from National Heart, Lung, and Blood Institute, VA Health Services Research & Development, and University of Colorado School of Medicine. He has a research agreement with Bristol-Myers Squibb through the University of Colorado. He serves as the Deputy Editor for Circulation: Cardiovascular Quality and Outcomes. IJD reports grants from UK National Health Service National Institute for Health Research, and has received unrestricted research grants and holds shares in GlaxoSmithKline, outside of the submitted work. All other authors declare no conflicts of interests.Funding StatementThis work was supported by the National Institute on Alcohol Abuse and Alcoholism (U01-AA026224, U24-AA020794, U01-AA020790, U10-AA013566), and by the Department of Veterans Affairs Health Services Research & Development (C19 20-405) and Office of Research and Development (MVP000). Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The views and opinions expressed in this manuscript are those of the authors and do not necessarily represent those of the Department of Veterans Affairs or the United States Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review boards of VA Connecticut Healthcare System and Yale University. It has been granted a waiver of informed consent and is Health Insurance Portability and Accountability Act compliant.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to US Department of Veterans Affairs (VA) regulations and our ethics agreements, the analytic data sets used for this study are not permitted to leave the VA firewall without a Data Use Agreement. This limitation is consistent with other studies based on VA data. However, VA data are made freely available to researchers with an approved VA study protocol. For more information, please visit https://www.virec.research.va.gov or contact the VA Information Resource Center at VIReC@va.gov.